2014-11-14T16:00:57-06:00 2013-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 650N BETHESDA MD 208142930 990 2013-01-01 830431851 PATH VACCINE SOLUTIONS PATH 2062853500 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 OLIVIA POLIUS CHIEF FINANCIAL OFFICER 2062853500 2014-11-14 1 3019519090 2013 2015-11-30 17:44:51Z OLIVIA POLIUS 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 75383762 0 X WWW.PATH.ORG X 2006 WA SEE PART III, LINE 1. 8 3 0 0 0 0 51421659 58520241 0 1200 691377 875409 17107 2365 52130143 59399215 28102003 28816531 0 0 0 0 0 0 0 12062025 8673859 40164028 37490390 11966115 21908825 142045531 166859076 2850743 6024155 139194788 160834921 X THE MISSION OF PATH VACCINE SOLUTIONS (PVS) IS TO IMPROVE THE HEALTH OF CHILDREN IN LOW-INCOME COUNTRIES BY ACCELERATING THE DEVELOPMENT OF VACCINES THAT WILL BE EFFECTIVE AND AFFORDABLE FOR THOSE WHO NEED THEM MOST. FROM INITIAL DISCOVERY THROUGH CLINICAL TRIALS, PVS WORKS WITH COMMERCIAL PARTNERS, SUCH AS VACCINE MANUFACTURERS AND BIOTECHNOLOGY FIRMS, AND NONPROFIT PARTNERS, SUCH AS UNIVERSITIES AND RESEARCH INSTITUTIONS, TO SHORTEN THE TIMELINE FOR VACCINE DEVELOPMENT.PVS WORKS WITH PARTNERS TO DEVELOP NEW VACCINES BY PROVIDING FUNDING AND EXPERTISE IN PRECLINICAL DEVELOPMENT, MANUFACTURING, AND CLINICAL DEVELOPMENT, WITH A FOCUS ON LOW-RESOURCE COUNTRIES. IN RETURN, PARTNERS AGREE TO TERMS THAT HELP ENSURE THE RESULTING PRODUCTS ARE AFFORDABLE AND AVAILABLE IN DEVELOPING COUNTRIES. 0 0 37490390 28816531 1200 PVS WORKS TO PREVENT DEATHS FROM PNEUMONIA, INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS, POLIO, AND DIARRHEA AMONG CHILDREN AROUND THE WORLD. WE ACCELERATE THE DEVELOPMENT OF SAFE, EFFICACIOUS, AND AFFORDABLE VACCINES IN PARTNERSHIP WITH PUBLIC AND PRIVATE GROUPS. IN 2013 PVS MADE ADDITIONAL PROGRESS IN ADVANCING RESEARCH AND DEVELOPMENT OF A NUMBER OF PROMISING PNEUMOCOCCAL VACCINE CANDIDATES AND RELATED TECHNOLOGIES. WE ANALYZED THE RESULTS OF A PHASE 1 TRIAL OF A PNEUMOCOCCAL WHOLE CELL VACCINE WE ARE DEVELOPING IN PARTNERSHIP WITH BOSTON CHILDREN'S HOSPITAL AND PREPARED FOR A PHASE 1 AND 2 STUDY IN ADULTS AND TODDLERS IN KENYA. WE ALSO ADVANCED A PNEUMOCOCCAL CONJUGATE VACCINE CONTAINING TEN SEROTYPES (PCV-10) IN PARTNERSHIP WITH THE SERUM INSTITUTE OF INDIA. TAILORED TO CHILDREN'S NEEDS IN LOW-RESOURCE COUNTRIES, THE PCV-10 CANDIDATE IS DESIGNED TO BE AFFORDABLE AND FOCUSES ON VARIETIES OF THE PNEUMOCOCCUS BACTERIUM THAT ARE PREVALENT IN THESE COUNTRIES. INFECTION WITH ROTAVIRUS IS A MAJOR CAUSE OF SEVERE DIARRHEA AND DEATH AMONG YOUNG CHILDREN IN LOW-RESOURCE COUNTRIES. PVS ACCELERATES THE INTRODUCTION OF SAFE, AFFORDABLE, AND EFFECTIVE ROTAVIRUS VACCINES BY PROVIDING TECHNICAL AND FINANCIAL SUPPORT TO EMERGING-COUNTRY MANUFACTURERS. IN PARTNERSHIP WITH BHARAT BIOTECH OF INDIA, WE CONDUCTED A PHASE 3 TRIAL TO DETERMINE THE EFFICACY OF ONE OF THESE VACCINES. WE ACCUMULATED SUFFICIENT CASES TO HAVE THE DATA REVIEWED BY THE STUDY'S DATA AND SAFETY MONITORING BOARD. THE VACCINE WAS SHOWN TO SIGNIFICANTLY REDUCE SEVERE ROTOVIRUS DIARRHEA BY MORE THAN HALF (56 PERCENT DURING THE FIRST YEAR OF LIFE) WITH PROTECTION CONTINUING INTO THE SECOND YEAR OF LIFE. THE VACCINE EFFICACY COMPARES FAVORABLY WITH THAT OF THE CURRENTLY LICENSED VACCINES BUT WILL BE FAR MORE AFFORDABLE. WE SUBMITTED A LICENSE APPLICATION TO THE DRUG CONTROLLER GENERAL OF INDIA AND RECEIVED A FAVORABLE RECOMMENDATION IN AUGUST 2013 FROM INDIA'S NEW DRUG ADVISORY COMMITTEE. WE ALSO SUPPORTED THE GOVERNMENT TO HOST A SCIENTIFIC CONFERENCE TO PRESENT THE RESULTS. SUBSEQUENTLY, WE COMPLETED THE PHASE 3 STUDY AND FINAL DATA SET, WHICH SHOWED ROBUST EFFICACY OF THE VACCINE IN THE SECOND YEAR OF LIFE.IN ADDITION, IN 2013 PVS COMPLETED A PHASE 1 STUDY OF A NOVEL, NON-REPLICATING ROTAVIRUS VACCINE. BECAUSE THE RESULTS WERE ENCOURAGING, WE BEGAN PREPARATIONS FOR A PHASE 2 TRIAL IN SOUTH AFRICA. PVS ALSO PARTNERS WITH PUBLIC- AND PRIVATE-SECTOR ORGANIZATIONS TO ADVANCE THE RESEARCH AND DEVELOPMENT OF VACCINES AGAINST THE TWO LEADING BACTERIAL CAUSES OF DIARRHEA, SHIGELLA AND ENTEROTOXIGENIC ESCHERICHIA COLI (ETEC). KEY ACTIVITIES IN 2013 INCLUDED COMPLETING A PHASE 1 TRIAL OF THE INACTIVATED TRIVALENT WHOLE CELL SHIGELLA VACCINE; INITIATING A PHASE 1 STUDY OF A LIVE, ATTENUATED SHIGELLA SONNEI VACCINE CANDIDATE; COMPLETING A PHASE 1 TRIAL OF A LIVE, ATTENUATED ETEC VACCINE; CONDUCTING A PHASE 1 TRIAL OF THAT SAME VACCINE WITH A NOVEL ADJUVANT (AN INGREDIENT THAT BOOSTS THE BODY'S IMMUNE RESPONSE); AND CONVENING A WORKSHOP OF LEADING SCIENTIFIC EXPERTS TO ASSESS OPTIONS FOR A COMBINED SHIGELLA/ETEC VACCINE. 37490390 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 X 8 3 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 WA X X OLIVIA POLIUS CHIEF FINANCIAL OFFICER 2062853500 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 STEVEN B DAVIS CHAIR 1.00 39.00 X X 0 481239 41628 JACQUELINE D SHERRIS VICE CHAIR (UNTIL 10/23/13) 1.00 39.00 X X 0 208881 27439 PENNY HEATON VICE CHAIR (BEGAN 10/23/13) 1.00 0.00 X X 0 0 0 ERIC G WALKER TREASURER (UNTIL 10/23/13) 1.00 39.00 X X 0 352054 34611 OLIVIA POLIUS TREASURER (BEGAN 10/23/13) 1.00 39.00 X 0 99511 6116 AMIE E BATSON DIRECTOR (BEGAN 10/23/13) 1.00 39.00 X 0 193128 10579 DAN LASTER DIRECTOR / GENERAL COUNSEL 1.00 39.00 X 0 225160 35498 DAVID KASLOW DIRECTOR (BEGAN 10/2/13) 1.00 39.00 X 0 322463 39519 CHRIS KARP DIRECTOR 1.00 0.00 X 0 0 0 TOM BREWER DIRECTOR (UNTIL 10/23/13) 1.00 2.00 X 0 0 0 DAVID ALLI BOARD SECRETARY 20.00 20.00 X 0 151874 28657 0 2034310 224047 0 0 1 0 NORTHERN TRUST 50 S LASALLE ST CHICAGO IL 60675 ASSET MANAGEMENT 159621 1 424773 58095468 10335 58520241 HONORARIA 900099 1200 1200 1200 977007 977007 15882949 15984547 -101598 -101598 -101598 OTHER REIMBURSEMENTS 900099 2365 2365 2365 59399215 1200 0 877774 23135831 23135831 5680700 5680700 60744 60744 167747 167747 740237 740237 5387 5387 207666 207666 4108 4108 2500 2500 1764828 1764828 88242 88242 91781 91781 SUBCONTRACTS 5358615 5358615 LAB SUPPLIES 89058 89058 EQUIPMENT R&M & PROCURE 49221 49221 STORAGE 26722 26722 17003 17003 37490390 37490390 0 0 5020984 5006227 57535405 69342564 214274 217893 32953 37428 30494 19165 6934 79255703 92252505 142045531 166859076 2850743 6024155 2850743 6024155 X 150 139194788 160834771 139194788 160834921 142045531 166859076 21908825 -268692 0 X 0 1 X 1 0 X X X 0 0 0 PATH 911157127 BOX 7 1 37490390 1 37490390 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 37428 30494 6934 6934 1 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 74794 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES INTERNATIONAL DEVELOPMENT 17634 EAST ASIA AND THE PACIFIC 0 0 GRANTMAKING 1219363 EUROPE 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 797465 EUROPE 0 0 PROGRAM SERVICES INTERNATIONAL DEVELOPMENT 1512 EUROPE 0 0 GRANTMAKING 803906 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 53 NORTH AMERICA 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 12690 RUSSIA AND THE NEWLY INDEPENDENT STATES 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 352360 RUSSIA AND THE NEWLY INDEPENDENT STATES 0 0 GRANTMAKING 373598 SOUTH AMERICA 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 34658 SOUTH ASIA 0 10 PROGRAM SERVICES PRODUCT DEVELOPMENT 757285 SOUTH ASIA 0 0 PROGRAM SERVICES INTERNATIONAL DEVELOPMENT 275069 SOUTH ASIA 0 0 GRANTMAKING 2347989 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 127983 SUB-SAHARAN AFRICA 0 0 GRANTMAKING 935845 0 0 0 10 0 10 2927417 5204787 8132204 EAST ASIA AND PACIFIC PRODUCT DEVELOPMENT 171532 CHECK/WIRE EAST ASIA AND PACIFIC PRODUCT DEVELOPMENT 1145996 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 75000 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 112292 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 121554 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 176575 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 318485 CHECK/WIRE RUSSIA AND THE NEWLY INDEPENDENT STATES PRODUCT DEVELOPMENT 373598 CHECK/WIRE SOUTH ASIA INTERNATIONAL DEVELOPMENT 58593 CHECK/WIRE SOUTH ASIA INTERNATIONAL DEVELOPMENT 68749 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 18261 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 34000 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 98919 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 99402 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 124406 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 174911 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 200000 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 271688 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 298054 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 375690 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 523035 CHECK/WIRE SUB SAHARAN AFRICA PRODUCT DEVELOPMENT 935845 CHECK/WIRE EAST ASIA AND PACIFIC PRODUCT DEVELOPMENT -98165 CHECK/WIRE 13 5 1 0 0 0 0 0 PART I, LINE 2: SUBRECIPIENTS ARE REQUIRED TO SUBMIT PROGRESS REPORTS, WHICH ARE REVIEWED BY RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS TO ENSURE THAT PROGRAM GOALS ARE ATTAINED IN ACCORDANCE WITH AGREEMENT REQUIREMENTS. THE RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS CONTACT SUBRECIPIENTS WITH QUESTIONS AND FOLLOW UP ON ANY CONCERNS. IN SOME CASES, SUBAWARD TERMS MAY REQUIRE SPECIFIED DELIVERABLES IN ADDITION TO, OR IN LIEU OF, TECHNICAL AND FINANCIAL REPORTS. DISCRETIONARY ON-SITE VISITS ARE ALSO CONDUCTED TO EVALUATE BOTH COMPLIANCE WITH THE SCIENTIFIC OBJECTIVES OF THE PROJECT AND APPROPRIATENESS OF THE SUBRECIPIENT'S ADMINISTRATIVE SYSTEMS AND PROCESSES. 1 THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA 701 20TH STREET SOUTH AB 1170 BIRMINGHAM AL 352940111 636005396 501(C)(3) 9121 PRODUCT DEVELOPMENT UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVE NE BOX 359472 SEATTLE WA 98195 916001537 501(C)(3) 13087 PRODUCT DEVELOPMENT TULANE EDUCATIONAL FUND 1430 TULANE AVENUE TB-32 NEW ORLEANS LA 701122632 720423889 501(C)(3) 18000 PRODUCT DEVELOPMENT JOHNS HOPKINS UNIVERSITY (JHU) 3400 N CHARLES ST BALTIMORE MD 21218 131687001 501(C)(3) 25887 PRODUCT DEVELOPMENT CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI OH 45229 310833936 501(C)(3) 27144 PRODUCT DEVELOPMENT WALTER REED ARMY INSTITUTE OF RESEARCH (WRAIR) 503 ROBERT GRANT DRIVE SILVER SPRING MD 20910 520664528 GOVERNMENT 27500 PRODUCT DEVELOPMENT BIOPROCESS TECHNOLOGY CONSULTANTS INC (BPTC) 12 GILL STREET SUITE 5450 WOBURN MA 01801 100002382 N/A 27537 PRODUCT DEVELOPMENT SEATTLE CHILDREN'S HOSPITAL 4800 SAND POINT WAY NE SEATTLE WA 98105 911156519 501(C)(3) 30179 PRODUCT DEVELOPMENT BOARD OF TRUSTEES OF LELAND STANFORD JUNIOR UNIVERSITY 340 PANAMA ST STANFORD CA 943056203 941156365 501(C)(3) 34235 PRODUCT DEVELOPMENT UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVE NE BOX 359472 SEATTLE WA 98195 916001537 501(C)(3) 39212 PRODUCT DEVELOPMENT TUFTS UNIVERSITY 136 HARRISON AVENUE BOSTON MA 02111 042103634 501(C)(3) 42096 PRODUCT DEVELOPMENT WALTER REED ARMY INSTITUTE OF RESEARCH (WRAIR) 503 ROBERT GRANT DRIVE SILVER SPRING MD 20910 520664528 GOVERNMENT 42258 PRODUCT DEVELOPMENT OKLAHOMA STATE UNIVERSITY 203 WHITEHURST HALL STILLWATER OK 74078 736017987 GOVERNMENT 60000 PRODUCT DEVELOPMENT JOHNS HOPKINS UNIVERSITY (JHU) 3400 N CHARLES ST BALTIMORE MD 21218 131687001 501(C)(3) 63215 PRODUCT DEVELOPMENT JOHNS HOPKINS UNIVERSITY (JHU) 3400 N CHARLES ST BALTIMORE MD 21218 131687001 501(C)(3) 69353 PRODUCT DEVELOPMENT UNIVERSITY OF PITTSBURGH OFFICE OF RESEARCH 123 UNIVERSITY PLACE LOWER LOBBY PITTSBURGH PA 15213 250965591 501(C)(3) 88084 PRODUCT DEVELOPMENT FAMILY HEALTH INTERNATIONAL (FHI) 360 PO BOX 13950 2224 E NC HWY 54 DURHAM NC 27713 237413005 501(C)(3) 100000 PRODUCT DEVELOPMENT SEATTLE CHILDREN'S HOSPITAL 4800 SAND POINT WAY NE SEATTLE WA 98105 911156519 501(C)(3) 111816 PRODUCT DEVELOPMENT CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC 1600 CLIFTON ROAD ATLANTA GA 30333 586051157 GOVERNMENT 123746 PRODUCT DEVELOPMENT JOHNS HOPKINS UNIVERSITY (JHU) 3400 N CHARLES ST BALTIMORE MD 21218 131687001 501(C)(3) 138713 PRODUCT DEVELOPMENT WALTER REED ARMY INSTITUTE OF RESEARCH (WRAIR) 503 ROBERT GRANT DRIVE SILVER SPRING MD 20910 520664528 GOVERNMENT 139837 PRODUCT DEVELOPMENT WALTER REED ARMY INSTITUTE OF RESEARCH (WRAIR) 503 ROBERT GRANT DRIVE SILVER SPRING MD 20910 520664528 GOVERNMENT 160000 PRODUCT DEVELOPMENT UNIVERSITY OF ALABAMA AT BIRMINGHAM 701 20TH STREET SOUTH AB 1170 BIRMINGHAM AL 352940111 636005396 501(C)(3) 183350 PRODUCT DEVELOPMENT FINA BIOSOLUTIONS LLC 9610 MEDICAL CENTER DRIVE SUITE 200 200 ROCKVILLE MD 20850 205448275 N/A 193453 PRODUCT DEVELOPMENT WALTER REED ARMY INSTITUTE OF RESEARCH (WRAIR) 503 ROBERT GRANT DRIVE SILVER SPRING MD 20910 520664528 GOVERNMENT 199657 PRODUCT DEVELOPMENT CHILDREN'S HOSPITAL BOSTON 300 LONGWOOD AVENUE BOSTON MA 02115 042774441 501(C)(3) 200342 PRODUCT DEVELOPMENT CHILDREN'S GMP LLC 262 DANNY THOMAS PLACE MEMPHIS TN 38105 620646012 501(C)(3) 225889 PRODUCT DEVELOPMENT NOVARTIS VACCINES AND DIAGNOSTICS 350 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139 942754624 N/A 238463 PRODUCT DEVELOPMENT JOHNS HOPKINS UNIVERSITY (JHU) 3400 N CHARLES ST BALTIMORE MD 21218 131687001 501(C)(3) 256204 PRODUCT DEVELOPMENT WALTER REED ARMY INSTITUTE OF RESEARCH (WRAIR) 503 ROBERT GRANT DRIVE SILVER SPRING MD 20910 520664528 GOVERNMENT 315451 PRODUCT DEVELOPMENT MOUNT SINAI SCHOOL OF MEDICINE ONE GUSTAVE L LEVY PLACE NEW YORK NY 100296574 136171197 501(C)(3) 575000 PRODUCT DEVELOPMENT JOHNS HOPKINS UNIVERSITY (JHU) 3400 N CHARLES ST BALTIMORE MD 21218 131687001 501(C)(3) 1113278 PRODUCT DEVELOPMENT JOHNS HOPKINS UNIVERSITY (JHU) 3400 N CHARLES ST BALTIMORE MD 21218 131687001 501(C)(3) 1656608 PRODUCT DEVELOPMENT NOVAVAX INC 20 FIRSTFIELD ROAD ROCKVILLE MD 20878 222816046 N/A 1950450 PRODUCT DEVELOPMENT LIQUIDIA TECHNOLOGIES INC 419 DAVIS DRIVE SUITE 100 DURHAM NC 27713 201926605 N/A 2149874 PRODUCT DEVELOPMENT PATH 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 830431851 501(C)(3) 12702315 GENERAL SUPPORT INFECTIOUS DISEASE RESEARCH INSTITUTE (IDRI) 1616 EASTLAKE AVENUE EAST SEATTLE WA 98102 911608978 501(C)(3) -171196 PRODUCT DEVELOPMENT CHILDREN'S HOSPITAL BOSTON 300 LONGWOOD AVE BOSTON MA 02115 042774441 501(C)(3) -26686 PRODUCT DEVELOPMENT DIAGNOSEARCH LIFE SCIENCES INC 1140 AVENUE OF THE AMERICAS 9TH FLOOR NEW YORK NY 10036 030507787 N/A -25000 PRODUCT DEVELOPMENT 17 5 PART I, LINE 2: SUBRECIPIENTS ARE REQUIRED TO SUBMIT PROGRESS REPORTS, WHICH ARE REVIEWED BY RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS TO ENSURE THAT PROGRAM GOALS ARE ATTAINED IN ACCORDANCE WITH AGREEMENT REQUIREMENTS. THE RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS CONTACT SUBRECIPIENTS WITH QUESTIONS AND FOLLOW UP ON ANY CONCERNS. IN SOME CASES, SUBAWARD TERMS MAY REQUIRE SPECIFIED DELIVERABLES IN ADDITION TO, OR IN LIEU OF, TECHNICAL AND FINANCIAL REPORTS. IN ADDITION, DISCRETIONARY ON-SITE VISITS ARE CONDUCTED TO EVALUATE BOTH COMPLIANCE WITH THE SCIENTIFIC OBJECTIVES OF THE PROJECT AND THE APPROPRIATENESS OF THE SUBRECIPIENT'S ADMINISTRATIVE SYSTEMS AND PROCESSES. 0 0 0 0 0 0 0 0 0 STEVEN B DAVIS CHAIR 0 420801 0 59938 0 500 0 30600 0 11028 0 522867 0 0 JACQUELINE D SHERRIS VICE CHAIR (UNTIL 10/23/13) 0 208637 0 0 0 244 0 24563 0 2876 0 236320 0 0 ERIC G WALKER TREASURER (UNTIL 10/23/13) 0 351054 0 0 0 1000 0 25448 0 9163 0 386665 0 0 AMIE E BATSON DIRECTOR (BEGAN 10/23/13) 0 178128 0 15000 0 0 0 9625 0 954 0 203707 0 0 DAN LASTER DIRECTOR / GENERAL COUNSEL 0 224390 0 0 0 770 0 24497 0 11001 0 260658 0 0 DAVID KASLOW DIRECTOR (BEGAN 10/2/13) 0 322388 0 0 0 75 0 28491 0 11028 0 361982 0 0 DAVID ALLI BOARD SECRETARY 0 151874 0 0 0 0 0 18058 0 10599 0 180531 0 0 PART I, LINE 3 PATH VACCINE SOLUTIONS RELIES ON A RELATED ORGANIZATION, PATH, TO DETERMINE COMPENSATION. PATH USES THE FOLLOWING TO ESTABLISH COMPENSATION OF THE EXECUTIVE DIRECTOR: - INDEPENDENT COMPENSATION CONSULTANT - COMPENSATION COMMITTEE - COMPENSATION SURVEY OR STUDY - APPROVAL BY THE BOARD OR COMPENSATION COMMITTEE FORM 990, PART VI, SECTION B, LINE 11 THE FORM 990 WAS PREPARED BY THE OUTSIDE ACCOUNTING FIRM USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE FINAL 990 WAS SENT TO THE BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE CFO SIGNED THE RETURN. FORM 990, PART VI, SECTION B, LINE 12C PVS HAS A WRITTEN CONFLICT OF INTEREST POLICY UNDER WHICH ALL PVS BOARD MEMBERS AND OFFICERS MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. PVS DOES NOT HAVE EMPLOYEES. PVS IS A SUPPORTING ORGANIZATION TO PATH WITHIN THE MEANING OF IRC SECTION 509(A)(3), AND PVS CONTRACTS WITH PATH FOR MANAGEMENT SERVICES. PATH HAS A WRITTEN CONFLICT OF INTEREST POLICY UNDER WHICH ALL PATH BOARD MEMBERS, OFFICERS, AND STAFF ABOVE A DESIGNATED LEVEL MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL PVS AND PATH DISCLOSURE FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. FORM 990, PART VI, SECTION C, LINE 19 PVS'S FINANCIAL STATEMENTS, GOVERNING DOCUMENTS, AND CONFLICT OF INTEREST POLICY ARE MADE AVAILABLE TO THE PUBLIC UPON REQUEST. PATH 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 911157127 GLOBAL HEALTH WA 501(C)(3) LINE 7 N/A 0 PATH DRUG SOLUTIONS 280 UTAH AVENUE SUITE 250 SAN FRANCISCO CA 94080 943384500 DEVELOPMENT & DISTRIBUTION OF SAFE, EFFECTIVE, AND AFFORDABLE MEDICINES CA 501(C)(3) LINE 11A PATH 1 ORGANIZATION FOR APPROPRIATE TECHNOLOGY IN HEALTH 25 BUILDING B0 SHOTA RUSTAVELI STR KYIV UP REDUCE THE TB BURDEN IN UKRAINE UP N/A N/A PATH 1 FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND 207 ROUTE DE FERNEY 1218 LE GRAND-S GENEVA SZ EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH SZ N/A N/A PATH 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0